Cite
HARVARD Citation
Glintborg, B. et al. (2017). A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry. Annals of the rheumatic diseases. 76 (8), pp. 1426-1431. [Online].